VERU (VERU) $6.66, Goes Poof.
Veru Provides Update on FDA Advisory Committee Meeting
Market Cap Plunges from...
Revive Therapeutics (RVVTF) Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA
TORONTO, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life...
Revive (RVVTF) Hits a Snag?
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
First our summary."FDA provided communication that...
Revive Therapeutics (RVVTF) Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
TORONTO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life...
VERU Inc. (VERU) $24. High Risk, Minimal Reward?
Pre-FDA Approval Play. The Shares Are Now in the Hands of Fast Money Traders.
You Can't Kiss all the...
What is NAC (N-Acetyl-L-Cysteine)? (Dr Eric Berg)
https://youtu.be/oPdGOrqTfhA
What is NAC good for? (and How Much to Take?)
Revive’s Quarterly Report, Discussion, and a Video!
With 5,000 hospitalizations reported daily (150,000 a month), contracting Covid is not something to be taken lightly - after you get it....
Revive Therapeutics Gains 25% on Positive FDA Comments.
The Company stated yesterday that it "has received positive comments from the FDA in regard to the Company’s request to determine and...
Bavarian Nordic (BVNRY) Bags $119 Million Order from Joe Biden.
We Were up 80% on Bavarian For a Little While There. The Stock Looks Better Today, Then When we Originally Added...
Could Bucillamine be the Key to Preventing Lockdowns in Places Like North Korea?
Revive Therapeutics Nears FDA-EUA Approval or Non-approval, for Bucillamine its Novel Anti-inflammatory and Antioxidant. Bucillamine 'Boosts' Glutathione, a Natural Substance Found...
Latest article
IA Initiates Analyst Coverage of Principal Solar (Press Release).
Principal Solar, Inc.Mon, March 20, 2023 at 7:30 AM EDT
Institutional Analyst, Inc....
Selling ARK (ARKK) & Buying AXS Short Innovation (SARK) ETF.
Going Short the Market. No Long Dissertation, No Rush. Market Risk Has Appeared, With Minimal Upside, So Time To Act.
We’re Bearish, but we’re up 257% in Provention Bio (PRVB) Today.
And up 416%, from Adding it to 2022 Watch List!
Great way to wake up after a night of...
